Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live attenuated monovalent DENV3 vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Live attenuated monovalent DENV3 vaccine (specifically the rDEN3Δ30/31-7164 strain) is a vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of dengue virus serotype 3 infection. It is derived from the wild-type DENV-3 Sleman/78 virus and contains a 30-nucleotide deletion (Δ30) and a 31-nucleotide deletion (Δ31) in the 3' untranslated region (UTR) for attenuation, along with a Vero cell adaptation mutation at nucleotide position 7164 (NS4B Val→Ala). The vaccine is designed to elicit a robust neutralizing antibody and T-cell response against DENV-3. It is also utilized as a component of the tetravalent dengue vaccine candidates TV003 and TV005, and has been evaluated in clinical trials to study the effects of pre-existing dengue immunity on subsequent vaccination responses.
- Other names
- monovalent rDEN3Δ30/31-7164rDEN3-delta-30/31
02
Targets
BCR (Immunoglobulin G B Cell Receptor)γδ TCR (T-cell receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on live attenuated monovalent DENV3 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live attenuated monovalent DENV3 vaccine.